Lorazepam Dose for Seizure
For status epilepticus in adults, administer lorazepam 4 mg IV slowly (2 mg/min), and if seizures persist after 10-15 minutes, give an additional 4 mg IV dose. This is the FDA-approved dosing and represents the standard of care for seizure emergencies 1.
Adult Dosing
Intravenous Administration (Preferred Route):
- Initial dose: 4 mg IV given slowly at 2 mg/min 1
- Repeat dose: If seizures continue or recur after 10-15 minutes of observation, give another 4 mg IV slowly 1
- Maximum experience: Limited data exists for doses beyond 8 mg total 1
Intramuscular Administration (When IV Access Unavailable):
- Dose: 0.05-0.10 mg/kg IM (maximum 4 mg per dose) 2
- Repeat: May repeat every 10-15 minutes if needed 2
- Note: IM route is not preferred because therapeutic levels are not reached as quickly as IV 1
Pediatric Dosing
For children with status epilepticus:
- IV/IM dose: 0.05-0.10 mg/kg (maximum 4 mg per dose) 2
- Repeat interval: Every 10-15 minutes if seizures continue 2
- Important caveat: The FDA label states that safety in pediatric patients has not been established 1, though pediatric guidelines from the American Academy of Pediatrics support this weight-based dosing 2
For CAR T-cell related seizures (specialized pediatric context):
- Non-convulsive status epilepticus: 0.05 mg/kg IV (maximum 1 mg), repeat every 5 minutes up to 4 doses 3
- Convulsive status epilepticus: 0.1 mg/kg IV (maximum 2 mg), repeat after at least 1 minute up to 2 doses 3
Critical Implementation Points
Preparation Requirements:
- Have airway equipment immediately available before administration 1
- Ensure ability to provide ventilatory support 1
- Dilute with equal volume of compatible diluent before IV use 1
- Administer slowly with repeated aspiration to avoid intra-arterial injection 1
Common Pitfall - Underdosing: The most significant error in clinical practice is administering less than 4 mg in adults. A 2023 study found that 87% of patients who received less than 4 mg progressed to refractory status epilepticus, compared to only 62% who received the full 4 mg dose 4. Do not underdose based on arbitrary weight cutoffs - the FDA label specifies 4 mg for all adults ≥18 years 1.
Monitoring Requirements:
- Respiratory depression is the most important risk 1
- Monitor oxygen saturation continuously 2
- Be prepared to manage apnea, especially when combined with other sedatives 2
- Excessive sedation may add to post-ictal impairment 1
Comparison to Other Benzodiazepines
Current guidelines support lorazepam as first-line treatment alongside midazolam and diazepam 5, 6. Lorazepam offers advantages over diazepam: it has a longer duration of anticonvulsant activity (reducing seizure recurrence) and requires fewer repeat doses, though both are equally effective at initial seizure termination 7. The 2024 ACEP guidelines confirm that lorazepam, midazolam, and diazepam have similar efficacy for initial benzodiazepine treatment 5.
When Lorazepam Fails
If seizures persist after appropriate benzodiazepine dosing, proceed immediately to second-line agents. The 2024 ACEP guidelines recommend fosphenytoin, levetiracetam, or valproate with similar efficacy for benzodiazepine-refractory status epilepticus 5. Do not continue giving additional lorazepam beyond the recommended doses - this represents refractory status epilepticus requiring escalation of therapy 1.
Reversal Agent Warning: Flumazenil can reverse respiratory depression from lorazepam but will also eliminate anticonvulsant effects and may precipitate seizure recurrence 2. Use only for life-threatening respiratory depression when ventilatory support cannot be provided.